ATM Gene Mutations and Breast Cancer Radiotherapy Responses
Author Information
Author(s): JM Appleby, JBP Barber, E Levine, JM Varley, AMR Taylor, T Stankovic, J Heighway, C Warren, D Scott
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK
Hypothesis
Can screening for mutations in the ATM gene predict severe reactions to radiotherapy in breast cancer patients?
Conclusion
The study found no ATM mutations in breast cancer patients with severe reactions to radiotherapy, suggesting that screening for these mutations may not be useful for predicting adverse reactions.
Supporting Evidence
- No mutations typical of A-T heterozygotes were detected in the patients tested.
- The study suggests that ATM mutations do not confer clinical radiosensitivity.
- Only 5% of patients typically show severe reactions to radiotherapy.
Takeaway
The researchers looked for specific gene mutations in breast cancer patients who had bad reactions to radiation treatment, but they didn't find any, meaning the gene test might not help predict who will have severe side effects.
Methodology
The study screened 16 highly radiosensitive breast cancer patients and 7 patients with other cancers for ATM mutations using a restriction endonuclease fingerprinting assay.
Limitations
The sample size was relatively small, and the study only included patients with severe reactions, which may not represent the broader population.
Participant Demographics
The study included 16 breast cancer patients and 7 patients with other cancers, all of whom had severe reactions to radiotherapy.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website